Summit Therapeutics Inc.
SMMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.84 | -0.02 | 0.18 | -0.11 |
| FCF Yield | -1.11% | -4.75% | -5.14% | -29.38% |
| EV / EBITDA | -59.80 | 1,650.30 | -13.56 | -2.09 |
| Quality | ||||
| ROIC | 0.08% | -48.34% | -8.70% | -97.01% |
| Gross Margin | 0.00% | 0.00% | -256.99% | 100.00% |
| Cash Conversion Ratio | 0.64 | 0.12 | 0.53 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -6.44% | 43.52% |
| Free Cash Flow Growth | -85.00% | -82.17% | 42.10% | -50.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 34.64 | -2.33 | 0.80 |
| Interest Coverage | 0.04 | -5.45 | -13.55 | -306.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.01 | 0.00 |
| Cash Conversion Cycle | -112.76 | -474.86 | 46,892.00 | 4,907.02 |